Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Atopic Dermatitis

Taro Pharmaceuticals

Status and phase: Completed; Phase 2

Conditions: Dermatitis, Atopic

Treatments: Drug: DSXS

Study type: Interventional

Funder types: Industry

Identifiers

NCT02595008

DSXS 1502

Details and patient eligibility

About

this study is to evaluate the potential of DSXS to suppress HPA axis function in patients with moderate to severe atopic dermatitis.

Full description

The objective of this study is to evaluate the potential of DSXS to suppress HPA axis function in patients with moderate to severe atopic dermatitis.

The secondary objectives are to evaluate to evaluate adverse event (AE) profiles of DSXS administered to patients with moderate to severe atopic dermatitis.

Enrollment: 24 patients

Sex: All

Ages: 2+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with a definite clinical diagnosis of stable atopic dermatitis

Exclusion criteria

• Patient is under the age of 2

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

24 participants in 1 patient group

DSXS topical product

Experimental group

Description:

treatment with DSXS twice daily for 28 days

Treatment:

Drug: DSXS